US Diabetes Market Driven By Sedentary Lifestyle, Rising Obesity Levels and Unhealthy Dietary Habits

US represented the world’s third largest diabetes patient pool with more than 27 Million diabetes patients in 2015. Projections from the report suggest that the diabetes drug market in the US is expected to grow at a CAGR of nearly 11% during 2016-2021, reaching revenues worth more than US$ 60 Billion by 2021.  

A new report published by IMARC Group titled “US Diabetes Market Report: 2016 – 2020” provides a deep insight into the diabetes market in the US. The report finds that the US represented the world’s third largest diabetes patient pool with more than 27 Million diabetes patients in 2015. The study suggests that people who are obese, overweight or aged above 65 years are more prone to the risks of diabetes. As per IMARC Group estimates, more than half of the  total US population is either obese or overweight which is mainly due to their sedentary lifestyles, lack of physical exercise and unhealthy dietary habits. Furthermore, the number of people aged 65 years and older have steadily increased in the US since the 1960’s. From around 9% of the total population in 1960, this age group accounted for nearly 15% of the entire US population in 2015. Driven by the rising prevalence of diabetes and the fact that the United States has one of the highest per capita healthcare expenditures, the market for diabetes drugs is expected to exhibit strong growth in the coming years. Projections from the report suggest that the diabetes drug market in the US is expected to grow at a CAGR of nearly 11% during 2016-2021, reaching revenues worth more than US$ 60 Billion by 2021.

Browse full report at: http://www.imarcgroup.com/US-diabetes-market

The report provides population and prevalence rates of diabetes by type, region, gender and age group. Findings from the report suggest that Type-2 diabetes is more prevalent than Type-1 diabetes and currently accounts for the majority of all diagnosed cases of diabetes. In terms of regions, urban areas have a higher prevalence of diabetes as compared to rural areas. Based on gender, females currently account for the majority of the total diabetes patients. Based on age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients in the US followed by the age group 60-79 and 20-39.

The report has also segmented the US diabetes market on the basis of drug types. The market currently consists of oral anti-diabetics and insulin with insulin accounting for the majority of the total sales. For each of the two drug types, the report also provides historical market trends, market breakup by class, key players and market outlook. Based on class, DPP-IV inhibitors represent the biggest class in the oral anti-diabetics market while long acting insulin represent the biggest class in the US insulin market.

This report provides an analytical and statistical insight into the US diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in the United States. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the US diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the US diabetes market in any form.

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

Contact Us

IMARC Group
Tel: +91-120-415-5099
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: http://www.imarcgroup.com
Follow us on twitter: @imarcglobal

US Generic Drug Market to Reach US$ 141.5 Billion by 2021

Generic drugs have low research & development requirements. As a result, the costs involved in developing and manufacturing them are significantly lower than their branded counterparts. This allows generic manufacturers to price their drugs considerably lower compared to branded drugs. This has ultimately enabled the government, third-party payers and patients to save billions of dollars on healthcare expenditures.

A recently released report by IMARC Group titled “US Generic Drug Market – Industry Trends, Competitive Landscape, Opportunities and Outlook” provides a deep insight into the generic drugs market in the US. Over the last three decades, the US generic drug market has experienced robust growth and currently represents the world’s biggest market for generic drugs. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the US. The report cites several factors that are currently catalysing the growth of the US generic drug market. One of the major factors that has contributed to the growth of this market is the patent expiry of a number of blockbuster branded drugs. Once branded drugs go off-patent, manufacturers can launch generic versions of these drugs. As these drugs have low research & development requirements, the costs involved in developing and manufacturing them are significantly lower than branded drugs. This allows generic manufacturers to price their drugs considerably lower compared to branded drugs. This has ultimately enabled the government, third-party payers and patients to save billions of dollars on healthcare expenditures. Other growth inducing factors include aging population, increasing prevalence of chronic diseases and incentives offered to physicians and pharmacists to promote generics. According to the report, the market for generic drugs in the US reached values worth US$ 74.5 Billion in 2015, representing a CAGR of 13.3% during 2010-2015. Estimates by IMARC Group further suggest that the market is expected to grow at a CAGR of 11% during 2016-2021 reaching figures worth US$ 141.5 Billion by 2021.

Browse full report at: http://www.imarcgroup.com/us-generics-market

The report has bifurcated the market on the basis of branded and unbranded generics. Currently, unbranded generics dominate the market and account for the majority of the total generic prescription volumes. The report has further segmented the market on the basis of distribution. Some of the key purchasers of generic drugs in the US include Red Oak Sourcing, Walgreens Boots Alliance, McKesson One Stop, Econdisc Contracting Solutions, etc. The report has also provided a detailed competitive landscape analysis covering the key players operating in this market. At present, Teva represents the largest generic manufacturer in the US accounting for around a fifth of the total generic sales. Other major players include: Mylan Labs Inc., Sandoz, Endo/Par and Sun Pharmaceutical.

This report provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the US. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

Contact Us

IMARC Group
Tel: +91-120-415-5099
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: http://www.imarcgroup.com
Follow us on twitter: @imarcglobal